Preliminary results from phase I clinical trials with those inhibitors demonstrated a response rate ranging from 31% to 40% with durable responses (>1 year) in patients with advanced hematologic malignancies and a positive activity in solid tumors with IDH mutations, such as cholangiocarcinomas and low-grade gliomas. Here, IDH2 is linked to glioma.